TP53 and outcome in DLBCL: not only the coding region.

摘要

P53, the first tumor suppressor identified, has a key role in maintaining genomic stability, particularly in inhibiting the damaging effect of oncogene activation. p53 modulates the transcription of genes that govern major defenses against tumor growth.2 p53 also interacts with numerous cellular proteins, particularly those controlling programmed cell death. These interactions with DNA and proteins explain its critical function against cancer. Mutation of TP53 has been associated with a wide range of cancers, particularly hematologic cancers and DLBCL.3 TP53 messenger RNA (mRNA) is composed of 4 regions: the 5' untranslated region, which promotes translation and has a role in the stability of mRNA; a coding sequence (CDS); the 3'UTR, which contains regulatory sequences and binding sites for microRNA (miRNA); and a poly-A tail, which is important for the nuclear export, translation, and stability of mRNA. TP53 mutations associated with cancers are of 3 types: acquired tumor-associated mutations of the CDS, germline mutations found in Li-Fraumeni syndrome, and germline polymorphisms.